Skip Navigation

Annals of Oncology 2007 18(7):1282-1283; doi:10.1093/annonc/mdm275
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Medioni, J
Right arrow Articles by Oudard, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medioni, J
Right arrow Articles by Oudard, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Complete cerebral response with sunitinib for metastatic renal cell carcinoma

The first 10% of the full text of this article appears below.

Renal cell carcinoma (RCC) is a relatively rare cancer, representing 2–3% of the neoplasms in the adult population. Metastasis is in 30% of cases synchronous to the diagnosis of RCC. The most frequent common sites of metastasis include lung, liver, bone, brain and adrenal gland [1]. Brain metastasis from RCC is responsible for significant mortality [2].

RCC is characterized by the inactivation of the von Hippel–Lindau tumour-suppressor gene, which results in the deregulation of hypoxia response genes, including an overproduction of . . . [Full Text of this Article]

J Medioni1, O Cojocarasu1, J-L Belcaceres1, P Halimi2 and S Oudard1,*

1 Department of Medical Oncology
2 Department of Radiology, Georges Pompidou European Hospital, Paris, France

* Correspondence to: Dr Stéphane Oudard, Medical Oncology Department, Georges Pompidou European Hospital, 20 Leblanc Street, 75015 Paris, France. (E-mail: stephane.oudard@hop.egp.ap-hop-paris.fr)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Massard, J. Zonierek, M. Gross-Goupil, K. Fizazi, C. Szczylik, and B. Escudier
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Ann. Onc., October 22, 2009; (2009) mdp411v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M. A. Rudek, A. Sparreboom, and S. D. Baker
Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
Clin. Cancer Res., October 1, 2009; 15(19): 6062 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
Q. Zhou and J. M. Gallo
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Neuro-oncol, January 1, 2009; 11(3): 301 - 310.
[Abstract] [Full Text] [PDF]